Free Trial
NYSE:ATNM

Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis

Actinium Pharmaceuticals logo
$1.29 +0.17 (+15.18%)
(As of 12/20/2024 05:31 PM ET)

About Actinium Pharmaceuticals Stock (NYSE:ATNM)

Key Stats

Today's Range
$1.13
$1.29
50-Day Range
$1.12
$1.94
52-Week Range
$1.10
$10.24
Volume
1.08 million shs
Average Volume
438,404 shs
Market Capitalization
$40.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.40
Consensus Rating
Moderate Buy

Company Overview

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.

Actinium Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
25th Percentile Overall Score

ATNM MarketRank™: 

Actinium Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 828th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Actinium Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Actinium Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Actinium Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Actinium Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Actinium Pharmaceuticals is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Actinium Pharmaceuticals has a P/B Ratio of 0.98. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for ATNM.
  • Dividend Yield

    Actinium Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Actinium Pharmaceuticals does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ATNM.
  • Search Interest

    Only 6 people have searched for ATNM on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.00% of the stock of Actinium Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 27.50% of the stock of Actinium Pharmaceuticals is held by institutions.

  • Read more about Actinium Pharmaceuticals' insider trading history.
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Stock News Headlines

Actinium Pharmaceuticals 2024 Stockholder Meeting Outcomes
Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress
No one’s talking about these Trump trades
As you likely know, the “Trump bump” launched stocks to record highs after he secured his second reelection bid. Now, Trump and his team are coming to gut government regulation – and it’s going to create some incredible market opportunities. But while the masses chase large-cap tech and so-called AI stocks, a small circle of traders are using a strange but tactical method to find a pool of “hidden Trump trades.”
Actinium highlights development updates for Iomab-B, Actimab-A, Iomab-ACT
Actinium Pharma Q3 Loss Narrows
See More Headlines

ATNM Stock Analysis - Frequently Asked Questions

Actinium Pharmaceuticals' stock was trading at $5.24 at the beginning of the year. Since then, ATNM stock has decreased by 75.4% and is now trading at $1.29.
View the best growth stocks for 2024 here
.

Actinium Pharmaceuticals, Inc. (NYSE:ATNM) posted its earnings results on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.02.

Actinium Pharmaceuticals shares reverse split on the morning of Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Actinium Pharmaceuticals' top institutional investors include Geode Capital Management LLC (2.20%), State Street Corp (1.93%), Los Angeles Capital Management LLC (0.57%) and XTX Topco Ltd (0.46%).
View institutional ownership trends
.

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Fitbit (FIT) and OHR Pharmaceutical (OHRP).

Company Calendar

Last Earnings
8/05/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Web
N/A
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.40
High Stock Price Target
$21.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+473.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$-48,820,000.00
Pretax Margin
-50,512.35%

Debt

Sales & Book Value

Annual Sales
$81,000.00
Book Value
$1.31 per share

Miscellaneous

Free Float
29,324,000
Market Cap
$40.24 million
Optionable
Optionable
Beta
0.07
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:ATNM) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners